Key result
Ex vivo platelet aggregation testing for acetylsalicylic acid dosing showed 40% of patients required 30 mg/day, 50% required 100 mg/day, and 10% required 300-500 mg/day for complete inhibition.
Why the study?
Does individual dosing of acetylsalicylic acid guided by platelet aggregation testing ensure complete platelet inhibition in patients with cardiovascular diseases?
Population
108 patients with cardiovascular diseases
Design
Cohort
Authors
Loading...
May support platelet testing to guide aspirin dosing in cardiovascular disease; leaves open whether this improves outcomes.
Observational (n=108)
Does individual dosing of acetylsalicylic acid guided by platelet aggregation testing ensure complete platelet inhibition in patients with cardiovascular diseases?
Individualized dosing of acetylsalicylic acid guided by platelet aggregation testing reveals that 10% of cardiovascular patients are nonresponders to standard 100 mg/day doses and require higher doses for effective platelet inhibition.
Syrbe et al. (2001) conducted an observational in Cardiovascular diseases (n=108). Ex vivo platelet aggregation testing was evaluated on Dose of acetylsalicylic acid necessary to inhibit platelet aggregation. Ex vivo platelet aggregation testing for acetylsalicylic acid dosing showed 40% of patients required 30 mg/day, 50% required 100 mg/day, and 10% required 300-500 mg/day for complete inhibition.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: